Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor... see more

Recent & Breaking News (OTCQB:NWBO)

NW BIO ANNOUNCES COMPLETION OF DCVAX®-DIRECT PHASE I TRIAL RECRUITMENT

PR Newswire July 16, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.

PR Newswire July 9, 2014

INVESTOR ALERT - Andrews & Springer LLC Is Investigating Northwest Biotherapeutics, Inc. For Possible Violations of Securities Laws - NWBO

Business Wire July 9, 2014

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Northwest Biotherapeutics, Inc. (NWBO) To Contact The Firm

PR Newswire July 4, 2014

INVESTOR ALERT: Investigation of Northwest Biotherapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP

Business Wire July 1, 2014

Robbins Arroyo LLP Is Investigating the Officers and Directors of Northwest Biotherapeutics, Inc. on Behalf of Shareholders

PR Newswire July 1, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.

Business Wire June 25, 2014

NW BIO REAFFIRMS DCVAX®-DIRECT CLINICAL TRIAL INTERIM DATA ANNOUNCEMENTS

PR Newswire June 20, 2014

SHAREHOLDER ALERT: Investigation on Behalf of Northwest Biotherapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith

Business Wire June 19, 2014

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Northwest Biotherapeutics, Inc.

PR Newswire June 19, 2014

Investor Alert: Investigation into Northwest Biotherapeutics, Inc. Announced by Holzer & Holzer, LLC

Business Wire June 19, 2014

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against Northwest Biotherapeutics, Inc. - NWBO

Business Wire June 19, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northwest Biotherapeutics, Inc. - NWBO

PR Newswire June 19, 2014

NW BIO NAMED TO TWO RUSSELL INDEXES

PR Newswire June 16, 2014

DCVAX-DIRECT TRIAL UPDATE INDICATES FURTHER POSITIVE RESPONSES; 3 CASE STUDIES SHOW NO LIVE TUMOR CELLS IN INJECTED TUMORS

PR Newswire June 11, 2014

DCVAX®-L PHASE III TRIAL INITIATED IN GERMANY

PR Newswire June 10, 2014

MarketExclusive.com - SummerStreet Research Partners Reiterates Buy Rating of Northwest Biotherapeutics, Inc.

Accesswire June 4, 2014

NW BIO TO PRESENT AT JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE

PR Newswire June 4, 2014

NW BIO REFUTES MORE FALSE CLAIMS BY FEUERSTEIN

PR Newswire May 29, 2014

NW BIO TO HOLD CONFERENCE CALL TO DISCUSS EARLY RESULTS OF DCVAX®-DIRECT ONGOING PHASE I/II TRIAL

PR Newswire May 27, 2014